GeoVax Labs (NASDAQ:GOVX) Stock Rating Reaffirmed by HC Wainwright

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 143.90% from the stock’s current price.

GeoVax Labs Trading Up 3.0 %

GeoVax Labs stock opened at $3.28 on Tuesday. The stock has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $2.70. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($2.47) EPS for the quarter. On average, sell-side analysts anticipate that GeoVax Labs will post -7.41 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs at the end of the most recent quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.